Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Dermatology

Journal Scan / Research · October 01, 2023

Efficacy of Adjuvant Dabrafenib and Trametinib Therapy in Patients With Resected BRAF-Mutated Melanoma

Melanoma research


Additional Info

Melanoma research
Adjuvant dabrafenib and trametinib for patients with resected BRAF -mutated melanoma: DESCRIBE-AD real-world retrospective observational study
Melanoma Res. 2023 Oct 01;33(5)388-397, JL Manzano, J Martin-Liberal, LA Fernández-Morales, G Benítez, J Medina Martínez, M Quindós, A García-Castaño, O Fernández, RV Simo, M Majem, L Bellido, P Ayala de Miguel, B Campos, E Espinosa, JA Macías Cerrolaza, I Gil-Arnaiz, D Lorente, A Rodriguez-Lescure, VN Perez, R López Castro, MG Gramaje, T Puértolas, JF Rodriguez Moreno, L Espasa Font, G Belaustegui Ferrández, P Cerezuela-Fuentes

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading